Truist initiated coverage on Tandem Diabetes Care with a new price target
$TNDM
Medical/Dental Instruments
Health Care
Truist initiated coverage of Tandem Diabetes Care with a rating of Hold and set a new price target of $24.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/16/2025 | $24.00 | Hold | Truist |
| 4/10/2025 | $20.00 | Neutral | Mizuho |
| 3/5/2025 | $45.00 → $22.00 | Overweight → Equal-Weight | Morgan Stanley |
| 3/4/2025 | $35.00 → $24.00 | Buy → Neutral | Citigroup |
| 3/3/2025 | $38.00 → $22.00 | Overweight → Equal Weight | Wells Fargo |
| 2/28/2025 | $35.00 → $25.00 | Outperform → Mkt Perform | Bernstein |
| 12/2/2024 | $45.00 | Equal-Weight → Overweight | Morgan Stanley |
| 11/6/2024 | $42.00 | Outperform | Bernstein |
Truist initiated coverage of Tandem Diabetes Care with a rating of Hold and set a new price target of $24.00
Mizuho initiated coverage of Tandem Diabetes Care with a rating of Neutral and set a new price target of $20.00
Morgan Stanley downgraded Tandem Diabetes Care from Overweight to Equal-Weight and set a new price target of $22.00 from $45.00 previously
SD - TANDEM DIABETES CARE INC (0001438133) (Filer)
8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)
8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)
For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy
For Immediate Release: November 07, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Monday, the FDA issued a Safety Communication warning consumers, health care providers, and health care facilities not to use recalled saline (0.9% sodium chloride) and sterile water medical products manufactured by Nurse Assist, LLC. On November 6, Nurse
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2025 results after the financial markets close on Wednesday, August 6, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI0d
Tandem continues to build its technology ecosystem to expand choice and personalization for people living with diabetes Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology now works with Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring (CGM) sensor. The Company has initiated an early access program in the United States (U.S.), and intends to scale availability in the second half of 2025. "Diabetes management is not one-size-fits-all and it is critical for people living with diabetes to be able to personalize their
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes. The Abbott sensor, currently under development, will combine glucose and ketone sensing technology that aims to help people living with diabetes detect early ketone rise to avoid life-threatening diabetic ketoacidosis. "Integrating our advanced insulin delivery systems with Abbott's future glucose-ketone sensor has the potential to help
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2025 results after the financial markets close on Wednesday, August 6, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI0d
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2025. First Quarter 2025 Highlights, Financial Results Compared to First Quarter 2024 Achieved record first quarter sales with worldwide growth of 22% Increased pump sales in the United States by 19% on a GAAP basis and 17% on a non-GAAP(1) basis, on strong shipment growth and average selling price improvement Delivered 5 point adjusted EBITDA(1) margin increase Approximately 30% of U.S. lives now covered through pharmacy benefits for Tandem Mobi Benefits of Control-IQ Technology were featured for a fourth time i
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2025 results after the financial markets close on Wednesday, April 30, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI72222
SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)
SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)
SC 13G - TANDEM DIABETES CARE INC (0001438133) (Subject)
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude "JC" Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620151195/en/Jean-Claude "JC" Kyrillos (Photo: Business Wire) "JC brings deep experience in healthcare and a great balance of technical, operational, and leadership skills from multipl
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ:TNDM) investors that a lawsuit filed on behalf of investors that purchased Tandem securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ:TNDM) investors that a lawsuit filed on behalf of investors that purchased Tandem securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' opti